Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from HLS Therapeutics Inc ( (TSE:HLS) ).
HLS Therapeutics Inc. reported a 21% increase in adjusted EBITDA for Q2 2025 and a 29% rise year-to-date, with significant growth in cash from operations. The company made substantial debt repayments and expanded its cardiovascular portfolio by licensing Canadian rights to NEXLETOL and NEXLIZET from Esperion Therapeutics. These developments are expected to strengthen HLS’s market position and support its growth trajectory, with plans to launch the new products in Canada by Q2 2026.
The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
HLS Therapeutics Inc’s overall score is primarily driven by its strong operational efficiency and strategic corporate events, which are offset by ongoing profitability issues reflected in a negative P/E ratio. Technical indicators suggest a potential buying opportunity, but the financial position must improve for a more favorable valuation.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is expanding its cardiovascular portfolio and is a leading Canadian-based company in cardiovascular risk reduction.
Average Trading Volume: 10,831
Technical Sentiment Signal: Hold
Current Market Cap: C$159.2M
See more data about HLS stock on TipRanks’ Stock Analysis page.